Rice Hall James & Associates LLC Purchases New Position in MaxCyte, Inc. (NASDAQ:MXCT)

Rice Hall James & Associates LLC acquired a new position in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 263,833 shares of the company's stock, valued at approximately $1,098,000. Rice Hall James & Associates LLC owned 0.25% of MaxCyte at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Valmark Advisers Inc. lifted its holdings in MaxCyte by 2.2% in the fourth quarter. Valmark Advisers Inc. now owns 115,654 shares of the company's stock worth $481,000 after buying an additional 2,478 shares during the period. Rhumbline Advisers increased its stake in shares of MaxCyte by 1.6% during the fourth quarter. Rhumbline Advisers now owns 153,655 shares of the company's stock valued at $639,000 after purchasing an additional 2,402 shares in the last quarter. Chevy Chase Trust Holdings LLC increased its stake in shares of MaxCyte by 0.6% during the fourth quarter. Chevy Chase Trust Holdings LLC now owns 1,339,829 shares of the company's stock valued at $5,574,000 after purchasing an additional 7,781 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of MaxCyte by 10.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,366 shares of the company's stock valued at $93,000 after purchasing an additional 2,154 shares in the last quarter. Finally, Gagnon Securities LLC increased its stake in shares of MaxCyte by 234.1% during the fourth quarter. Gagnon Securities LLC now owns 197,326 shares of the company's stock valued at $821,000 after purchasing an additional 138,257 shares in the last quarter. 68.81% of the stock is currently owned by hedge funds and other institutional investors.

MaxCyte Stock Down 2.7 %

Shares of NASDAQ MXCT traded down $0.11 on Friday, reaching $3.85. 348,701 shares of the company's stock traded hands, compared to its average volume of 549,374. MaxCyte, Inc. has a 12 month low of $3.16 and a 12 month high of $5.26. The business's 50 day simple moving average is $4.40 and its two-hundred day simple moving average is $4.05. The company has a market cap of $407.95 million, a price-to-earnings ratio of -11.33 and a beta of 1.30.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.